Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DEV2G0
|
|||
| Drug Name |
BIIB131
|
|||
| Synonyms |
Orniplabin; SMTP-7; SMTP7; SMTP 7; SMTP7; BIIB131; SCHEMBL2624852; GTPL12300; TMS-007; BCP33210; Stachybotrys microspora triprenyl phenol 7; HY-122311; CS-0083560; (2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Acute ischemic stroke [ICD-11: 8B11] | Phase 2 | [1] | |
| Company |
Biogen
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C51H68N2O10
|
|||
| Canonical SMILES |
CC(=CCCC(=CCCC1(C(CC2=C(C=C3C(=C2O1)CN(C3=O)CCCC(C(=O)O)N4CC5=C6C(=C(C=C5C4=O)O)CC(C(O6)(C)CCC=C(C)CCC=C(C)C)O)O)O)C)C)C
|
|||
| InChI |
InChI=1S/C51H68N2O10/c1-30(2)14-9-16-32(5)18-11-21-50(7)43(56)26-36-41(54)24-34-38(45(36)62-50)28-52(47(34)58)23-13-20-40(49(60)61)53-29-39-35(48(53)59)25-42(55)37-27-44(57)51(8,63-46(37)39)22-12-19-33(6)17-10-15-31(3)4/h14-15,18-19,24-25,40,43-44,54-57H,9-13,16-17,20-23,26-29H2,1-8H3,(H,60,61)/b32-18+,33-19+/t40-,43-,44-,50-,51-/m0/s1
|
|||
| InChIKey |
CRNDCHORWGDFGR-PXTWCNKMSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05764122) A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Biogen | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.